Sydney, June 16, 2026, 08:08 AEST
- Sigma Healthcare finished Monday at A$2.80, up 6.06%. The stock rose as the company ended talks with the UK’s Boots pharmacy group about a possible takeover. Bull Market Analysis
- The company said buying Boots doesn’t fit with its current strategy or capital budget.
- The next big test for investors is the FY26 full-year window. They are watching Chemist Warehouse sales, merger synergies, and debt. Sigma Co
Sigma Healthcare Ltd jumped Monday after Chemist Warehouse’s parent ended its talks to buy The Boots Group, removing a drag on the shares. Sigma closed at A$2.80, up 16 cents, or 6.06%. The stock changed hands between A$2.78 and A$2.86, market data showed. Reuters said Sigma climbed as much as 8.3% intraday. Sigma outperformed the S&P/ASX 200, which added 1.25% to 8,914.00 as other Australian shares also gained. Intelligent Investor
Deal headlines can shake up shares. Traders watch risks, debt loads, or if new stock will mean dilution. Dilution can leave holders with a smaller stake after a share sale. On June 10, Sigma said it was in early talks to buy Boots. By June 15, the board announced the discussions were off. Earlier, Reuters reported Boots could fetch US$10 billion.
Sigma’s decision to pull back looked aimed at keeping capital in check. “Investors appear to have breathed a sigh of relief,” Marc Jocum, senior product and investment strategist at Global X ETFs, told Reuters. News of the Boots talks had put Sigma under pressure as investors worried about how it would fund and integrate a deal. The group is still working through the Chemist Warehouse merger slated for 2025. Reuters
Sigma bulls are leaning on fresh momentum numbers. Group revenue climbed 14.9% to A$5.5 billion in the latest half. Normalised EBIT rose 18.7% to A$582.9 million, while normalised NPAT hit A$392.0 million, up 19.2%. EBIT excludes interest and tax. Australian Chemist Warehouse branded store sales jumped 17.2%, with like-for-like sales up 15.0%. CEO Vikesh Ramsunder said, “Our first half performance reinforces the strength of Sigma.” Sigma Co
Skeptics say dumping the Boots bid hasn’t erased Sigma’s international risk. The company is still pushing for growth overseas. Back in May, Sigma signed a memorandum with Greenlight Healthcare to open Chemist Warehouse stores in the UK. Sigma would take a 75% interest in a group of stores, with up to five to start. That’s a more measured move than buying Boots, but investors haven’t seen evidence yet that Chemist Warehouse can be scaled outside Australia. Sigma’s market cap was about A$32.3 billion as of Monday. The stock was still 14.11% off the 52-week high even after bouncing. Sigma Co
Investors are watching Sigma’s full-year numbers to see if it can keep sales momentum and deliver merger gains without a new big deal. Sigma’s own calendar doesn’t show dates yet, but market diaries put the preliminary full-year result on August 26 and the annual report on September 16. Normalised earnings, same-store Chemist Warehouse sales, net debt to EBITDA, and integration savings will be closely tracked. Sigma trades more as a growth stock with execution risk now than as a value play. The business looks sound, but a lot of positives are already in the price. Sigmahealthcare
